GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Change In Receivables

Curocell (XKRX:372320) Change In Receivables : ₩692.87 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Change In Receivables?

Curocell's change in receivables for the quarter that ended in Jun. 2024 was ₩46.18 Mil. It means Curocell's Accounts Receivable declined by ₩46.18 Mil from Dec. 2023 to Jun. 2024 .

Curocell's change in receivables for the fiscal year that ended in Dec. 2023 was ₩1,194.54 Mil. It means Curocell's Accounts Receivable declined by ₩1,194.54 Mil from Dec. 2022 to Dec. 2023 .

Curocell's Accounts Receivable for the quarter that ended in Jun. 2024 was ₩0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Curocell's liquidation value for the six months ended in Jun. 2024 was ₩-13,456.05 Mil.


Curocell Change In Receivables Historical Data

The historical data trend for Curocell's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Change In Receivables Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
55.79 -1.47 -480.41 -1,227.92 1,194.54

Curocell Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24
Change In Receivables -379.20 -848.72 547.85 646.69 46.18

Curocell Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₩692.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curocell  (XKRX:372320) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Curocell's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

2. In Ben Graham's calculation of liquidation value, Curocell's accounts receivable are only considered to be worth 75% of book value:

Curocell's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=29021.589-42477.643+0.75 * 0+0.5 * 0
=-13,456.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curocell Change In Receivables Related Terms

Thank you for viewing the detailed overview of Curocell's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Curocell Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell Headlines

No Headlines